To assess the effect of CCR5 on tumor progression, the CCL5/CCR5 pathway was inhibited by treatment with Maraviroc, an FDA-approved drug which inhibits the CCL5/CCR5 pathway and is used for the treatment of CCR5-trophic. Here, CCR5 is linked to neoplasm.